{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:40:12Z","timestamp":1784590812726,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ejphar.2009.10.023","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T08:15:40Z","timestamp":1255767340000},"page":"S1-S4","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S1","title":["Ten years of infliximab (Remicade\u00ae) in clinical practice: The story from bench to bedside"],"prefix":"10.1016","volume":"623","author":[{"given":"Freddy","family":"Cornillie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2009.10.023_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.ejphar.2009.10.023_bib2","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.023_bib4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis & Rheumatism (Arthritis Care & Research)"},{"key":"10.1016\/j.ejphar.2009.10.023_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0167-5699(00)01680-7","article-title":"Antibody humanization: a case of the \u2018Emperor's new clothes\u2019?","volume":"21","author":"Clark","year":"2007","journal-title":"Immunology Today"},{"key":"10.1016\/j.ejphar.2009.10.023_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","article-title":"Tumour-necrosis-factor antibody treatment in Crohn's disease","volume":"342","author":"Derckx","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.023_bib7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomized double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliot","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.023_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.023_bib10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimaeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2009.10.023_bib12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"4","author":"Maini","year":"1998","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.ejphar.2009.10.023_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.ejphar.2009.10.023_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2000.105948","article-title":"Treatment with anti-tumor necrosis factor \u03b1 (TNF-\u03b1) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions","volume":"42","author":"Oh","year":"2000","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejphar.2009.10.023_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.023_bib18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejphar.2009.10.023_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.023_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clim.2005.01.007","article-title":"Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model","volume":"115","author":"Shen","year":"2005","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib22","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis a randomized, controlled trial","volume":"50","author":"St.Clair","year":"2004","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.ejphar.2009.10.023_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejphar.2009.10.023_bib24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn's disease associated with spondyloarthropathy: effect of TNF\u03b1 blockade with infliximab on articular symptoms","volume":"356","author":"van den Bosch","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.023_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.2006.105379","article-title":"Prediction of anti-TNF clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease","volume":"56","author":"Van den Brande","year":"2007","journal-title":"GUT"},{"key":"10.1016\/j.ejphar.2009.10.023_bib27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic rheumatoid arthritis treatment in patients with recent-onset damage after 4years of response-driven","volume":"68","author":"van der Kooij","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.ejphar.2009.10.023_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2009.10.023_bib30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis & Rheumatism"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909009145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909009145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T00:50:38Z","timestamp":1544921438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299909009145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":30,"alternative-id":["S0014299909009145"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2009.10.023","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}